ArticleThe Journal of international medical research2026
Anti-tuberculosis drug treatment and adverse reactions in 546 children with tuberculosis in Chongqing, China: A 10-year retrospective study.
Article in The Journal of international medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundLong-term combination anti-tuberculosis regimens may lead to various types and severities of adverse drug reactions, potentially resulting in treatment discontinuation, interruption, or prolonged therapy.AimConsidering the lengthy duration of anti-tuberculosis combination regimens, it is crucial to monitor adverse drug reactions occurring during such treatment. This is the first hospital-based study conducted in western China to report adverse drug reactions and assess their prevalence and impact among children with tuberculosis receiving first-line anti-tuberculosis therapy.MethodsA retrospective study was conducted on registered tuberculosis cases at the Children's Hospital of Chongqing Medical University from 2014 to 2023. Data on demographic characteristics, treatment regimens, and adverse drug reactions were collected and evaluated. Statistical methods were used to analyze factors associated with adverse drug reactions.ResultsAmong 546 patients receiving anti-tuberculosis therapy, adverse drug reactions were reported in 476 (87.18%). Hyperuricemia was the most common adverse drug reaction (44.26%), followed by elevated liver enzymes without jaundice and elevated bile acids (10.38%) and leukopenia (8.31%). Most adverse drug reactions occurred within the first month of treatment (51.48%), whereas 33.44% persisted for >6 months. Pyrazinamide was the most frequently suspected causative drug (7.47%). Univariate analysis showed significantly higher adverse drug reaction rates among children aged 11-18 years, those with severe tuberculosis, those receiving the isoniazid + rifampicin + pyrazinamide + ethambutol + linezolid regimen, those on a recommended dose of rifampicin, and those receiving a high dose of pyrazinamide (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.